Bernard J. Zovighian - 07 May 2023 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
President
Signature
Linda J. Park, Attorney-in-Fact
Issuer symbol
EW
Transactions as of
07 May 2023
Net transactions value
-$333,307
Form type
4
Filing time
09 May 2023, 20:53:29 UTC
Previous filing
04 May 2023
Next filing
15 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Options Exercise $0 +5,003 +24% $0.000000 25,784 07 May 2023 Direct F1
transaction EW Common Stock Tax liability $206,143 -2,323 -9% $88.74 23,461 07 May 2023 Direct
transaction EW Common Stock Tax liability $127,164 -1,433 -6.1% $88.74 22,028 08 May 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Performance Rights Options Exercise $0 -5,003 -78% $0.000000 1,372 07 May 2023 Common Stock 5,003 $0.000000 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On May 7, 2020, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2023, the Compensation Committee of the Board of Directors determined that 78.48% of the target number of shares would vest as of May 1, 2023, and the actual number of shares vested are reflected on this Form 4.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.